Please ensure Javascript is enabled for purposes of website accessibility Takes Aim at Drug Prices

By Todd Campbell - Updated Oct 30, 2017 at 6:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Goliath retailer could be working on plans to revolutionize drug distribution.

Goliath Internet retailer (AMZN -7.16%) may have taken another step toward disrupting the pharmacy market. According to reports, Amazon has obtained pharmacy wholesale licenses in multiple states. The news shook pharmacy retailers such as CVS Health (CVS -5.39%), and drug distributors like McKesson Corp. (MCK -3.75%). Will we all be getting our next prescriptions filled by

Plans in the works

Amazon has been flirting with pharmacy retail for a long time. Founder Jeff Bezos was a former board member of the now-defunct online pharmacy retailer, in which Amazon itself was once a 40% owner. Ultimately, was a failed attempt at shaking up pharmacy distribution, but lessons learned could be shaping the second attempt.

A senior woman looks at products in a retail pharmacy store.


Earlier this year, Amazon was reportedly investigating how to create an internal pharmacy benefit manager. PBMs act as middlemen between healthcare payers, such as insurers, and drugmakers; they combine the buying power of multiple payers to negotiate lower prices, and take a small cut for their efforts. PBMs also work closely with patients to lower costs, by converting them to generic alternatives when possible and making sure they stick to treatment regimens so that they avoid hospitalization.

Amazon's efforts to build a PBM may currently be limited to internal use, but once it's built, there could be significant benefits to scaling it up by providing services to other big corporations. Amazon also appears to be toying with business models that allow it to take orders for prescription drugs and then coordinate with local pharmacies to fulfill them. This approach was reportedly being tested in Japan earlier this year.

A lot of money up for grabs

Spending on prescription medicines exceeds $300 billion in the U.S. alone, and carving away even a small slice of that huge number could provide enough incentive to convince Amazon to enter the market.

CVS Health and Walgreen Boots Alliance (WBA -8.39%) are the big kahunas in retail pharmacy, but they're far from the only companies that profit from drug distribution. Drug distributors that buy drugs at wholesale prices to resell them to PBMs and others generate billions of dollars in combined profits every year. The three biggest of these companies are McKesson, Cardinal Health (CAH -1.80%), and AmerisourceBergen (ABC -3.71%), and according to Drug Channels Institute, they account for 85% to 90% of the market. Over the past 12 months, these three companies produced a combined $6.95 billion in net income.

Chart of McKesson, Cardinal Health, and AmerisourceBergen trailing 12-month net income

McKesson, Cardinal Health, and Amerisource Bergen net income (trailing 12-month). Data by YCharts.

The next step is keeping its plans for reshaping the drug market close to the vest, so only time will tell how big of a splash it decides to make in the industry.

In preparation for potential competition from Amazon, don't be surprised if major companies look to band together to eliminate costs and insulate their market positions. Rumors are already swirling that CVS Health may be targeting an acquisition of Aetna (AET) to solidify its standing. There's no guarantee such a deal would win the favor of regulators, but it certainly hints at what could be coming down the pike in terms of mergers and acquisitions.

Regardless of how Amazon's plans shake out, patients will be watching closely in hopes that even the threat of a new low-cost competitor can provide some relief to sky-high drug prices.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned, Inc. Stock Quote, Inc.
$2,142.25 (-7.16%) $-165.12
Aetna Inc. Stock Quote
Aetna Inc.
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
$41.17 (-8.39%) $-3.77
Cardinal Health, Inc. Stock Quote
Cardinal Health, Inc.
$55.68 (-1.80%) $-1.02
McKesson Corporation Stock Quote
McKesson Corporation
$320.65 (-3.75%) $-12.51
AmerisourceBergen Corporation Stock Quote
AmerisourceBergen Corporation
$151.11 (-3.71%) $-5.82
CVS Health Corporation Stock Quote
CVS Health Corporation
$94.02 (-5.39%) $-5.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.